Health Services

All-day "executive physical" experiences with stacks of advanced tests—the yield-versus-harm math of what you actually detect earlier.

Sometimes "more care" means more deviation from standard-of-care, more tests, more procedures—and worse outcomes.

Prenuvo and the sensitivity tradeoffs, reading time, missed findings, and psychological effects of a "clean" scan.

A story about probability, base rates, and how luxury health services thrive on findings that keep customers returning.

MCED tests like Galleri—circulating tumor DNA signals, positive predictive value, and the still-open mortality question.

Elite hospital programs offering cardiovascular tests controversial in asymptomatic populations—evidence versus status.

"Hangover cures" and "immunity boosts"—thin evidence for healthy people, real risks, and a regulatory patchwork.

Private rehab clinics marketing NAD+ IVs as addiction treatment despite weak clinical evidence.

Quick telehealth access, private-pay coaching, compounded versions—when high demand meets weak oversight.

FDA warnings to 18 companies, hospitalizations from counterfeit products, and the authentication problem in luxury aesthetics.

The contested leap from biomarker shifts to meaningful outcomes—telomere length studies and what they don't prove.

What's actually supported versus advertised—FDA warnings, physiology of cold exposure, and claim propagation.

Removing "pro-aging factors" via apheresis—epigenetic age studies and the leap from biomarkers to healthspan.

FDA enforcement actions, documented harms, and the gap between approved stem cell uses and marketed claims.

BPC-157 and "research chemical" injectables—sparse human trials, contamination risks, regulatory boundaries.

Off-label, private-pay, fragmented regulation—protocols, monitoring, and pricing vary wildly.

Continuous glucose monitoring for non-diabetics—no strong evidence for outcomes, psychological feedback loop effects.

Technical limits, population bias in PRS, and the ethical line between disease prevention and optimization.

Switzerland's longevity-clinic ecosystem—biological age testing, cell therapy narratives, and the persistence of rejuvenation myths.

In-app LLM concierge uses your health profile for personalized guidance. The exclusivity is the assistant itself.

FDA-cleared AI builds a virtual "model of you" from MRI, labs, and genetics. A continuously trackable digital self, updated yearly.

70-sensor scan generates ~50M data points; visit takes under an hour with same-session doctor review.

AI-assisted coronary CT analysis quantifies plaque in ways basic cholesterol panels cannot. The premium baseline goes mainstream.

AI trained on massive embryo datasets promises standardized, non-invasive assessment. Clinics differentiate on "tech-forward" selection.

Machine learning detects rare viable sperm when embryologists cannot. Pattern recognition as instrument, not chatbot.

3D total-body photography creates rotatable avatars and flags lesion changes over time.

Function connects lab results to Claude, letting AI respond with guidance grounded in your data rather than generic advice. $365/year.

Can AI manufacture the feeling of "my doctor is always available"? The industrialization of exclusivity through machine mediation.

3D facial models from 2D images, surgical outcome simulation, patient-specific predictive modeling. When prediction becomes persuasion.

ML models infer systemic risk from retinal images. Quick, noninvasive, photogenic—perfect for executive physicals and longevity packages.

FDA's clinical decision support guidance draws lines between wellness and medicine. Which AI features are devices? The question shapes the industry.